BACKGROUND Heart failure (HF) trials initiated in the last century highlighted many differences between men and
A series of trials initiated in the last century highlighted many differences between men and women with heart failure (HF) (1) (2) (3) (4) (5) (6) (7) (8) . Of particular concern in these trials and other studies was the suggestion that, in common with other cardiovascular (CV) conditions, women were less well treated than men were (1-13).
Since those trials were initiated, much has changed in the assessment and management of patients with HF. Natriuretic peptides are now measured routinely (14, 15) . Betablockers are recommended for all patients with HF with reduced ejection fraction (HFrEF), whereas in the largest previous comparison of men and women were used in only 55% of patients (7) . Similarly, the indication for mineralocorticoid receptor antagonists (MRAs) has broadened to patients with mild symptoms, as has the indication for cardiac resynchronization therapy (the effectiveness of which had not even been demonstrated when many of the previous studies were conducted) (14, 15) . All of these changes may give a new perspective on the management of, and outcomes in, women with HFrEF.
Herein, we compared women and men with HF enrolled in the 2 most recent and largest randomized controlled trials of pharmacological therapy in patients with HFrEF (16, 17) . OUTCOMES. The primary outcome for both trials was the composite of first HF hospitalization or CV death.
In this study, we analyzed the primary outcome, its components, sudden death, pump failure death, non-CV death, and all-cause death in women compared with men. We have also reported recurrent hospitalizations for HF, all CV, non-CV, and all causes. All events except non-HF, non-myocardial infarction (MI), and nonstroke CV hospitalizations, and non-CV hospitalizations were adjudicated by the same clinical endpoint committee using prespecified criteria.
In both trials, health-related quality of life (HRQL) was measured at baseline in 13,061 patients using the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, which is scored from 0 to 100, with lower scores indicating a poorer HRQL (18). General quality of life was measured using the EQ-5D-3L in the PARADIGM-HF trial. Competing-risks regression, using the Fine-Gray method, was used to assess the outcomes. The primary outcome and CV death were analyzed accounting for the competing risk of non-CV death.
First, HF hospitalization was analyzed accounting for the competing risk of all-cause death. Sudden deaths were analyzed accounting for the competing BASELINE CHARACTERISTICS. The baseline characteristics in men and women are shown in Table 1 .
Women were on average 2 years older than men, had higher SBP, and had a higher heart rate. There was no significant difference in body mass index, but women were more often obese (33.4% women vs. 29.2% men).
PRE-EXISTING COMORBIDITIES.
Apart from hypertension (70.6% women vs. 65.5% men) and clinically significant valvular disease (5.3% vs. 4.6%), women were less likely to have a history of major comorbid conditions such as atrial fibrillation (AF) (32.6% vs.
36.4%), previous MI (30.0% vs. 45.4%), and stroke (7.4% vs 8.0%). As well as having a lower prevalence of coronary artery disease (CAD), women had a much lower rate of prior coronary revascularization.
Among non-CV comorbidities, women had a similar prevalence of diabetes (31.0% vs. 31.6%) but a lower prevalence of chronic obstructive pulmonary disease (8.5% vs. 13.1%). Women were also less likely to be current smokers (6.2% vs. 15.8%) and had lower intake of alcohol.
In the EQ-5D-3L state of health score, women were much more likely to report moderate to extreme anxiety or depression (44.0% in women vs. 29.0% in men; p < 0.0001) (PARADIGM-HF trial only). This was especially true of women with an ischemic etiology (Online Tables 1 and 2 ).
HF CHARACTERISTICS AND INVESTIGATIONS AT
BASELINE. As shown in Table 2 , fewer women had been living with a diagnosis of HF for >5 years (27.5%
vs. 31.4%) and had been hospitalized for HF less often than men (58.1% vs. 62.3%). They were also less likely to have an ischemic etiology (50.0% vs. 60.5%). Tables 3 and 4 .
Mean eGFR was lower in women and a higher proportion of women had an eGFR <60 ml/min/1.73 m 2 .
Women were more likely to be in a higher NYHA functional class and had lower (worse) median KCCQ scores. Most of the individual KCCQ domain scores were also lower in women ( Figure 1, Online Figure 1 ).
The EQ-5D-3L state of health score (PARADIGM-HF trial only) showed large differences between women and men in their mobility, ability to undertake usual activities, and ability to self-care (washing and dressing) (Online Table 1 ).
TREATMENT AT BASELINE. The rates of use of a diuretic, beta-blocker, and MRA were very similar in women and men ( Table 3 and Figure 2 . Looking at the components of this composite, the rate and risk of first hospitalization for HF was also lower in women (adjusted HR:
0.80; 95% CI: 0.72 to 0.89).
The risk of CV death was also lower, as were each of the 2 major modes of CV death (i.e., sudden death and pump failure death). The adjusted HRs for these outcomes (0.65 to 0.70) were lower than for HF hospitalization. Interestingly, the risk of non-CV death was also lower in women and, as a result, so was the risk of all-cause death (adjusted HR for non-CV death:
0.66; 95% CI: 0.52 to 0.83; HR for all-cause death:
0.68; 95% CI: 0.62 to 0.74).
When outcomes were examined according to investigator-reported etiology (nonischemic vs.
ischemic), men with both nonischemic and ischemic etiology did worse than women in the corresponding groups did (Online Table 7 , Online Figure 2 ). Among men, those with an ischemic etiology had higher mortality rates than did individuals with a nonischemic etiology. However, among women mortality did not vary by etiology (i.e., the "protection" Table 4) . Of these, 750 (25.1%) were due to HF in women and 3,569 (26.2%) were due to HF in men. Among women, 4.3% had >1 hospitalization for HF and the same was true for 6.4% of men (Online Table 8 Values are n (%), unless otherwise indicated. All outcomes have been adjusted for randomized treatment and region at baseline. Adjusted model has been adjusted for age, heart rate, systolic blood pressure, NT-proBNP, BMI, NYHA functional class, LVEF, and eGFR. All outcomes were tested for competing risks of all-cause and noncardiovascular (non-CV) death. Sudden death was tested for competing risk of all nonsudden deaths and pump failure death for all non-pump failure deaths. Non-CV death was tested for competing risk of CV death. *Additional adjusted for previous heart failure hospitalization.
Abbreviations as in Table 2 .
Dewan et al. OUTCOMES. As has been shown previously, women had better outcomes than men (2, 3, 7) . However, we did analyses additional to those carried out in previous clinical trial datasets. Because the ATMOSPHERE and PARADIGM-HF trials were more contemporary than prior studies, we had a measurement of NT-proBNP and were able to adjust for this most powerful of all prognostic variables in HF. Given the lower mortality rate in women than men, we also analyzed hospitalization for HF, taking account of the competing risk of death (and examined the total burden of HF hospitalizations by examining repeat events).
Even after adjusting for NT-proBNP, and other prognostic variables, women remained less likely to die than men. Indeed, the differential increased somewhat so that the adjusted risk of death from any cause was 32% lower in women, greater than that identified in the largest prior sex-based analysis in HF from the CHARM (Candesartan in Heart Failure:
Assessment of Reduction in Mortality and morbidity) trial (7). We also looked at the 2 major modes of CV death in HFrEF (i.e., sudden death and death from pump failure or progressive HF). Both were less common in women (and the lower risk was proportionally similar for each, in women compared with men). The explanation for this is unknown, although 1 possibility is the difference that has been described in cardiac remodeling between men and women, possibly aggravated by more unfavorable remodeling in response to ischemic injury in men (with a higher prevalence of CAD in men) (32, 33) .
In contrast to death, the lower risk of a first HF hospitalization was less marked: women were 20% Values are n, unless otherwise indicated. Incident rate ratios (IRRs) adjusted for age, previous HF hospitalization, heart rate, systolic blood pressure, NT-proBNP, BMI, NYHA functional class, LVEF, and eGFR.
Abbreviations as in Table 2 and 3.
less likely to be hospitalized for HF than men were.
This more modest relative risk may be because we accounted for the substantial competing risk of death.
Interestingly, the lower risk of HF hospitalization in women was apparent for second and subsequent (and not just first) admissions, and the sex difference was larger when repeat admissions were examined.
Moreover, the risk of hospitalization for any CV More expected from the difference in background CAD, the risk of MI was lower in women than in men.
Conversely, the risk of stroke was greater and may, in Dewan et al.
